LY01610

· Luye Pharma Group Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for LY01610, covering 2024-03-15 to 2024-03-15. Get the full timeline:

Most recent: Clinical Trial Update: Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer [Phase 3]